Functional Consequences of the Human Leptin Receptor ( LEPR ) Q223R Transversion by Stratigopoulos, George et al.
126 VOLUME 17 NUMBER 1 | JANUARY 2009 | www.obesityjournal.org
articles nature publishing group
Genetics
IntroductIon
Leptin plays a central role in the control of human body weight 
as evidenced by the profound effects on adiposity of null alleles 
for leptin (LEP) (1–4) or leptin receptor (LEPR) (5). A more 
difficult question is to what degree alleles of these genes—with 
more subtle effects on function or expression—contribute to 
human adiposity. This question is part of an even larger one: to 
what extent does allelic variation in genes in the known molec-
ular pathways regulating body weight contribute in additive or 
epistatic ways to human adiposity?
In mice, haploinsufficiency for Lep or Lepr increases adipos-
ity; and these effects are additive (6). In humans, comparable 
effects have been described for LEP (7). Genes in the signal-
ing pathways engaged by leptin and other peripheral (insulin, 
ghrelin, peptide YY) and central (melanocortin 4 receptor, 
neuropeptide Y, proopiomelanocortin, carboxypeptidase E) 
molecules have been examined by linkage and association 
studies for contributions to human adiposity. For example, 
the neuropeptide Y Leu7Pro polymorphism has been asso-
ciated with higher BMI in premenopausal women (8) and 
young Dutch males (9). The ghrelin Leu72Met variant is 
associated with the age of onset of obesity (10). Positive asso-
ciations with BMI have also been found with common vari-
ants of proopiomelanocortin and the melanocortin 4 receptor 
(11–13). For LEP, associations of the G19A and Gln25Gln 
(CAA to CAG) polymorphisms with increased body weight 
have been reported (14,15). Three missense variants Q223R, 
K109R, K656N in LEPR with allele frequencies >5% have 
been described, and their associations with adiposity exam-
ined (16,17) (see below).
LEPR is a member of the class I cytokine receptor family 
with six alternative transcripts. In the mouse, the longest iso-
form (Leprb) is predominately expressed in hypothalamic and 
other CNS neurons that control food intake, energy balance, 
and neuroendocrine function, while the shorter isoforms are 
predominately expressed in several peripheral tissues where 
their physiological roles are not entirely clear (18–21). Leptin 
binding to mouse LEPRb (mLEPRb) stimulates the activity 
of the associated Janus kinase 2, which initiates intracellular 
signaling by phosphorylating three sites on the intracellu-
lar domain of mLEPRb leading to transcriptional regulation 
of neuropeptides and other molecules that exert effects on 
energy homeostasis (22–33). All six LEPR isoforms share the 
same extracellular domain consisting of two cytokine recep-
tor homology (CRH) domains, CRH1 and CRH2, separated 
by an immunoglobulin (Ig)-like domain and followed by three 
fibronectin type III (F3) domains (Figure 1). CRH2 is sufficient 
for leptin binding and activation of LEPR (34,35). The CRH1 
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domain is less conserved, and does not seem to  participate in 
leptin binding or receptor activation (36).
The K109R polymorphism of LEPR causes a conservative 
change in the membrane-distal part of the LEPR extracellular 
domain (Figure 1). No apparent effect of K109R on BMI has 
been reported (16,37–42). K656N, a nonconservative change 
present in the membrane-proximal part of the LEPR extracel-
lular domain, shows no association with adiposity (16,37–43). 
The Q223R nonconservative change is located in the CRH1 
domain (Figure 1). A number of studies have reported associ-
ations of this variant with increased body weight and fat mass, 
whereas others failed to demonstrate the association (summa-
rized in Table 1).
The aim of this study was to examine the functional conse-
quences of Q223R by (i) assessing the effects of a humanized 
allele on body composition in the mouse; and (ii) measuring 
the functional activity of these Lepr alleles in cultured cells. 
Mice segregating for Lepr Q223R were generated, and gene 
dosage effects on adiposity and energy homeostasis were quan-
tified. No effects of this allele were apparent either in vivo or 
in vitro; relevant caveats are discussed below. We propose that 
this approach will be useful in vetting the biological relevance 
of nonsynonymous variants in genes-mediating putative effects 
on quantitative traits such as adiposity.
Methods and Procedures
humanized Lepr variant Q223r
A targeting construct was designed to use homologous recombination 
in embryonic stem (ES) cells to replace coding exon 4 of the mouse Lepr 
gene with a segment that was identical except for codon 223. The target-
ing construct contained a ~6 kb fragment (extending from a SwaI site 
to a PmeI site) that contains coding exon 4. The codon substitution was 
accomplished by oligonucleotide-directed mutagenesis coupled with 
PCR. Two overlapping fragments were generated by PCR that encom-
passed coding exon 4 and flanking sequences. The codon sequence 
alteration was designed to introduce a novel PvuI site and a novel TaqI 
site for diagnostic restriction digestions to identify the wild-type and 
novel alleles. The two overlapping fragments were digested with PvuI, 
ligated, and reamplified to generate one contiguous fragment contain-
ing the codon sequence alteration. This fragment was digested with 
Acc65I and EcoRV and used to replace a similar restriction fragment in 
the targeting construct. A floxed Pgk-neo cassette was inserted into the 
EcoRV site that is downstream of coding exon 4. All amplified segments 
were sequenced to eliminate clones with PCR-related sequence altera-
tions (Figure 1b). The construct was used for targeting 129P3/J ES 
cells. Three G418 resistant clones were identified to have homologous 
recombination at the PGK-neo cassette by PCR. However, only two 
independent clones were verified to contain the desired codon altera-
tion. Mice carrying the humanized Lepr 223R (equivalent to 222R in 
the mouse; for simplicity, it will be referred to as 223R) allele were gen-
erated by injecting the ES clone into C57BL/6J blastocysts. The floxed 
Pgk-neo cassette was excised by mating to deleter protamine Cre 129 
mice to prevent inadvertent effects due to interference from the Pgk-neo 
cassette. Mice carrying the neo-less allele were identified by PCR using 
primers flanking the Pgk-neo cassette insertion point.
The founder progeny (potentially capable of producing either 129 or B6 
gametes) were crossed to 129 mice and the DNA of F1 progeny interro-
gated for the targeted Lepr allele. F1 animals segregating for the targeted 
Lepr allele (therefore 129 throughout) were intercrossed to generate the 
animals whose phenotypes are described below.
husbandry
All mice were housed in groups of three to four per cage under a 12:12 
hour light–dark cycle in a barrier facility at 21 °C. A total of 13 223R/R, 
35 223Q/R, 18 223Q/Q male and 23 223R/R, 28 223Q/R, 16 223Q/Q 
female mice were fed a low-fat (LF) diet (9% of calories as fat; Purina 
Picolab no. 5058 chow; Granville Milling, Creedmoor, NC). In addition, 
12 223R/R, 23 223Q/R, 16 223Q/Q male and 12 223R/R, 16 223Q/R, 
11 223Q/Q female mice were fed a LF (Purina Picolab no. 5058 chow; 
Granville Milling) or a high-fat (HF) (65% of calories as fat; cat. no. 
D12492; Open Source Diets) diet starting at 4 weeks of age. Mice fed 
the LF diet from 4 weeks of age were switched to the HF diet at 121 days 
of age. All mice had ad libitum access to food and water throughout 
these studies.
Body mass and composition measurement
Mice were weighed weekly on an electronic scale starting on postnatal 
day 14. Immediately after weighing, body composition was determined 
by TD-NMR using a Minispec Analyst AD lean fat analyzer (Bruker 
Optics, Silberstreifen Germany). The TD-NMR was calibrated using 
mouse carcasses that ranged from 5 to 70 g in mass.
calorimetry and energy intake
150-day-old male mice (four 223Q/Q and four 223R/R) were individu-
ally caged in a LabMaster-CaloSys-Calorimetry System (TSE Systems, 
Bad Homburg, Germany) and trained to use the water dispenser. Mice 
were weighed before being placed in their cages. Indirect calorimetry 
was performed for ~96 h while the mice had free access to the LF diet. 
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Figure 1 Extracellular domain of the leptin receptor. (a) Subdomains 
and locations of common polymorphisms of LEPR. (b) Generation of 
mice with the “humanized” leptin receptor. 223Q to 223R substitution 
(Q223R) in mouse exon 4. Restriction sites used for genotyping are 
indicated. (c) Expression levels in the hypothalamus of the three 
genotypes at amino acid 223 of Leprb. Expression data were normalized 
to β-actin (N = 3). CK, cytokine receptor subdomain; CRH, cytokine 
receptor homology subdomain; F3, fibronectin type III subdomain; Ig, 
immunoglobulin.
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table 1 association studies of LEPR Q223r with human adiposity
Authors
Ethnicity/subject 






 Thompson et al. (42) Pima Indians 10 obese  
(body fat = 40 ± 5%)
10 lean (body 
fat = 23 ± 5%)
Obesity R-0.75 R Hom
 Chagnon et al. (58) White 99 families: 
522 subjects
4U increase 
of BMI, 5% 
increase in %fat
R-0.43 R Het/Hom
 Yiannakouris et al. (40) White, 120 17 years 
male and female
2.7U increase 
of BMI, 4.6% 








of BMI, 11% 
increase in fat 
mass
R-0.6 R Het/Hom
 Mattevi et al. (8) Brazilian men 
and women of 
European descent
123 overweight and  
30 obese (BMI > 30)
153 lean  
(BMI < 25)
2.8U increase  
of BMI
R-0.45 R Het/Hom
 Guizar-Mendoza et al. (60) Mexican male  
and female 
adolescent
55 obese  
(BMI = 31.1 ± 3.6)
48 lean (BMI = 
20.7 ± 3.1)
11% increase in 
% fat
R-0.6 R Het/Hom
 Fairbrother et al. (61) White 
postmenopausal 
women




 Echwald et al. (39) Danish  
adolescent males
156 obese (BMI ≥ 31) 205 lean  
(BMI =  
21.5 ± 2.2)
None with BMI
 Gotoda et al. (43) British white men 190 obese males  
(BMI > 28)
132 lean males 
(BMI< 22)
None with BMI R-0.43
 Matsuoka et al. (41) Japanese male  
and female
47 obese  
(BMI = 35 ± 6.5)
68 lean (BMI = 
21.6 ± 2.2)
None with BMI R-0.85
 Silver et al. (37) White 175 obese  
(BMI = 6.75 ± 9.6)
107 lean  
(BMI = 21 ± 1.4)
None with BMI
 Chagnon et al. (62) QFS/169 
families/314-325 
sib. pairs
114 obese (BMI ≥ 27) 167 lean  
(BMI < 27)
None with BMI R-0.51
 de Silva et al. (63) Nauruan males 232 obese (BMI = 37) None with BMI R-0.89
 Chagnon et al. (58) African-American 
115 families: 319 
subjects
None with BMI, 
% fat
R-0.51
 Stefan et al. (64) Pima Indians 268 with low  
subcut. fat
184 with high 
sub. fat
None with abd., 
sub. fat
R-0.33
 Ogawa et al. (65) Japanese  
middle-aged men 
and women
175 obese  
(BMI = 6.75 ± 9.6)
107 lean  
(BMI = 21 ± 1.4)
None with BMI R-0.85
 van der Vleuten et al. (66) FCH patients, 
diverse










 Wang et al. (67) Taiwanese male  
and female 
Aborigines
226 obese (BMI ≥ 27) 
33 extreme (BMI ≥ 35)
182 lean  
(BMI < 25)
None with BMI R-0.1
 Mergen et al. (68) Turkish male and 
female
262 obese (BMI ≥ 30) 138 lean  
(BMI ≤ 25)
None with BMI R-0.38
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period, and VO2 and VCO2 values were expressed in ml/kg/h. Mice 
were taken out of the calorimeter and fed the HF diet ad libitum for 
72 h. They were then returned to the calorimeter cages with ad lib access 
to the HF diet and studied for ~96 h as before. Data from only the last 
72 h on the HF and LF diets were analyzed, as the mice were allowed to 
acclimate during the first ~24 h. Energy intake was calculated by mul-
tiplying cumulative food intake for a 24-h period by the metabolizable 
energy present in the HF (5.24 kcal/g) and LF (3.56 kcal/g) diets.
real time Pcr
Total RNA was extracted from hypothalami of 15 mice of each of 
the three 223 genotypes and reverse transcribed using random hex-
amers (Invitrogen SuperScript III; Carlsbab, CA). Real-time PCR 
was performed in a LightCycler II (Roche, Pleasanton, CA) using 
the LightCycler FastStart DNA Master SYBR Green kit (Roche) 
according to the manufacturer’s specifications. The following Lepr 
exonic primers were used: 5′-CCTCTGCCCCCACTGAAAGACA; 
5′-GGGTCACTGTCACTCTGAAGTGCAA.
Lepr expression levels were normalized with β-actin using the 
following exonic primers: 5′-CTTTGCAGCTCCTTCGTTGC; 
5′-TCTGACCCATTCCCACCATC.
stat3 activation assay
Materials. Generation of anti-LEPRb antibody has been described 
previously (44). Antibody against Tyr705 phosphorylated STAT3 was 
purchased from Cell Signaling Technology (Boston, MA). Leptin 
was purchased from NHPP (Los Angeles, CA). mLEPRb/pCDNA3 
has been described previously (45). The function of the Δ65 trunca-
tion in the intracellular domain of mLEPRb has been described and 
LEPRbΔ65/pCDNA3 is the nonchimeric variant which was used pre-
viously (46). mLEPRb/pCDNA3 was used as a template for mutagen-
esis. mLEPRbR223/pCDNA3 was constructed using a two-stage PCR 
method.
First, the 5′ flanking primer (5′-CGACTCACTATAGGGAGACCC
AAGCTTG), and the antisense mutagenesis primer (5′-GACATCAGA
GGTGACCGAAAACTCACACC), were used to amplify the upstream 
fragment.
The 3′ flanking primer (5′-GACATCGATCACGTATAATTCAGCAT
AGCGGT), and the 5′ mutagenesis primer (5′-GGTGTGAGTTTTCGG
TCACCTCTGATGTC) were used to amplify the downstream fragment. 
These PCR products combined and used as template for a second round 
of PCR using the flanking primers listed above. This PCR product was 
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Figure 2 Body composition of mice fed the high-fat (HF) or low-fat (LF) diet by 223 genotype. Time course of (a) body weight, (b) lean mass, and 
(c) fat mass of male and female mice by genotype (at Lepr codon 223) fed the LF or HF diet. Body weight, lean and fat mass measurements of 
mice fed the HF diet were made every week from 14 to 130 days of age; an additional measurement was made at 190 days of age. For mice fed the 
LF diet, these measurements were made every week from 14 to 120 days of age. At day 121, their diet was switched to HF. Each data point is the 
arithmetic mean of all animals. Error bars represent s.e.m. For numbers of animals in each study, see Husbandry in Methods and Procedures section.
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sites. The presence of the desired mutation and the absence of adventi-
tious mutations was confirmed by DNA sequencing.
Cell lines and transfection. HEK 293 cells were maintained in a 
humidified incubator at 37 °C with 5% CO2. Dulbecco’s modified Eagle 
medium supplemented with 10% fetal bovine serum, penicillin, and 
streptomycin was used as growth medium. The appropriate LEPRb and 
luciferase reporter plasmids were transiently transfected into 293 cells 
in 12-well plates using Lipofectamine (Invitrogen). 500 ng LEPRb plas-
mid, 50 ng GAS-Luc (encodes STAT3-responsive γ interferon-activated 
sequence driven luciferase), and 50 ng pRL-TK (encodes Renilla luci-
ferase) was transfected per well.
Immunoblotting. Following transfection, cells were switched to serum-
free medium and stimulated for 6 h with various doses of leptin. Cells 
were harvested in lysis buffer (20 mmol/l Tris pH 7.4, 150 mmol/l NaCl, 
1% Nonidet P-40) and insoluble material was cleared by centrifugation. 
Lysate was denatured in 4× Laemmli buffer and resolved by sodium 
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE). 
SDS–PAGE gels were transferred to nitrocellulose membranes in 
Towbin buffer containing 0.02% SDS and 20% methanol. Membranes 
were blocked for 1 h in buffer containing 20 mmol/l Tris (pH 7.4), 
150 mmol/l NaCl, and 0.01% Tween 20 (wash buffer) supplemented 
with 3% bovine serum albumin (block buffer). Membranes were incu-
bated with primary antibody for 2 h at room temperature. Membranes 
were washed three times and incubated with a horseradish peroxidase 
conjugated secondary antibody for 1 h. Membranes were then washed 
three times, treated with luminescence reagent (Lumi-Light, Roche) 
and exposed to film.
Luciferase assays. Following transfection, cells were switched to 
serum-free medium and stimulated for 6 h with various doses of lep-
tin. Cells were lysed and assayed with the Stop-n-Glo dual luciferase 
reporter kit (Promega, Madison, WI) according to the kit’s instructions; 
GAS-Luc firefly luciferase activity was normalized for transfection effi-
ciency with Renilla luciferase from the constitutive pRL-TK plasmid.
statistical analysis
Changes in body composition over time of mice fed LF or HF diet 
up to days 120 or 190 were assessed using areas under the curves of 
body mass, lean mass, and fat mass over time for each mouse. One 
way ANOVA (StatView 5.0; SAS Institute) was used, grouping by sex, 
genotype, and diet. Effects of the LF and HF diet on energy intake and 
expenditure, RQ and VO2 were assessed by t-testing the arithmetic 
mean of the calorimetry readings over 72 h. Levels of statistical signifi-
cance were set at Pα < 0.05.
ethical use of animals
We certify that all applicable institutional and governmental regula-
tions concerning the ethical use of animals were followed during this 
research. All protocols were approved by the Columbia University 
Institutional Animal Care and Use Committee and were conducted in 
accordance with the National Institutes of Health Guide for the Care 
and Use of Laboratory Animals.
table 2 statistical analyses of body mass and composition measurements
Male Difference Male Difference Female Difference Female Difference
A Days 21–190
 Dependent  
 variable
HF: Q/Q,Q/R,R/R LF: Q/Q,Q/R,R/R HF: Q/Q,Q/R,R/R LF: Q/Q,Q/R,R/R
 Body weight F = 0.69,  
df = 2,48,  
P = 0.52
— F = 0.42,  
df = 2,63,  
P = 0.66
— F = 1.61,  
df = 2,36,  
P = 0.24
— F = 0.94,  
df = 2,64,  
P = 0.41
—
 Fat mass F = 1.92,  
df = 2,48,  
P = 0.19
— F = 0.33,  
df = 2,63,  
P = 0.71
— F = 2.49, 
df = 2,36,  
P = 0.13
— F = 0.31,  
df = 2,64,  
P = 0.73
—
 Lean mass F = 1.81,  
df = 2,48,  
P = 0.21
— F = 0.09,  
df = 2,63,  
P = 0.90
— F = 0.03,  
df = 2,36,  
P = 0.97
— F = 2.66,  
df = 2,64,  
P = 0.10
—
 % fat F = 2.47,  
df = 2,48,  
P = 0.13
— F = 0.37,  
df = 2,63,  
P = 0.69
— F = 2.06,  
df = 2,36,  
P = 0.17
— F = 0.24,  




 Dependent  
 variable
HF,LF HF vs. LF HF,LF HF vs. LF
 Body weight F = 6.40,  
df = 1,115,  
P = 0.07
— F = 8.10,  
df = 1,104,  
P = 0.06
—
 Fat mass F = 17.61,  
df = 1,115,  
P = 0.0002
+50% F = 49.27,  
df = 1,104,  
P < 0.0001
+54%
 Lean mass F = 185.51,  
df = 1,115,  
P < 0.0001
–27% F = 116.56,  
df = 1,104,  
P < 0.0001
–27%
 % fat F = 17.35,  
df = 1,115,  
P = 0.0003
+30% F = 55.65,  
df = 1,104,  
P < 0.001
+50%
ANOVA for body mass and body composition by genotype at Lepr 223 in mice fed high-fat (HF) or low-fat (LF) diets up to day 190. Area under the curve from data points 
taken every week was calculated for each mouse and grouped by (A) sex, diet, and genotype (up to day 190), or (B) sex and diet (up to day 120).




Body weight and composition
Exon 4 of mouse Lepr is 76% identical at the DNA level and 
70% identical at the amino acid level to the human LEPR. The 
substitution of the mouse wild-type glutamine residue (QCAG) 
with arginine (RCGA) did not affect Lepr expression in the 
hypothalamus of mice heterozygous and homozygous for RCGA 
(Figure 1c). Genotype did not affect body mass in homozygous 
(Q/Q, R/R) and heretozygous (Q/R) male or female mice from 
14 to 21 days of age (Figure 2a). Mice of all three genotypes 
were then fed the HF or the LF diet until 120 days of age. From 
14 to 120 days of age, there were effects of diet composition 
and sex—but not genotype—on changes in weight, lean and fat 
mass. (Figure 2; Table 2). Likewise, responses to the change to 
a HF diet at 120 days were unaffected by genotype at Lepr 223 
(Figure 3; Table 2).
calorimetry
Indirect calorimetry on Q/Q and R/R mice fed either the LF 
or HF diet showed, as expected, that mice on the LF diet had 
a higher RQ than mice on the HF diet; but this difference was 
unaffected by genotype at Lepr (Figure 4c). During these calor-
imetry studies, mice of neither genotype gained weight after 
3 days on the HF or LF diet (Figure 4a), and had the same 
energy intake (Figure 4b) and energy expenditure (Figure 4e) 
per day while being fed the HF or LF diet. A time course of 
VO2 per hour per body mass
2/3 indicated that the 24-h energy 
expenditure and diurnal patterns of energy expenditure were 
indistinguishable between Q/Q and R/R mice fed the HF or LF 
diets (Figure 4d).
In vitro signaling effects of codon 223 genotypes
To investigate a possible alteration in signaling capacity 
between the 223Q and 223R Lepr alleles, we transfected plas-
mids encoding, STAT3-signaling defective LeprΔ65C, native 
Leprb223Q or humanized Leprb223R into 293 cells for the analysis 
of downstream signaling after treatment with various doses 
of leptin. The analysis of STAT3 activation by the detection of 
Tyr705 phosphorylation on endogenous STAT3 by immunob-
lotting revealed no differences in the extent of phosphoryla-
tion of STAT3 by Leprb223Q or Leprb223R (Figure 5b). Similarly, 
when Leprb223Q or Leprb223R-mediated STAT3 transcriptional 
activation was assayed in 293 cells co-transfected with the 
STAT3-responsive GAS-luciferase reporter plasmid, no differ-
ences in leptin-dependent luciferase stimulation were detected 
between the two Leprb alleles over a range of leptin concentra-
tions (Student’s t-test, P > 0.05) (Figure 5a).
dIscussIon
The Q allele of LEPR is conserved in species from monotremes to 
humans (Ensemble; Genomic Sequence Alignment). The Q allele 








































































































Figure 3 Body weight and composition by Lepr 223 genotype of mice switched to the high-fat (HF) diet at 121 days, Time course of (a) body weight, 
and (b) fat mass of male and female mice fed a HF diet for 13 weeks. Week 1 begins at day 121 of age, when mice were switched to the HF diet. 
Each data point represents a mean of all animals. Error bars represent s.e.m. Data analyzed by ANOVA. For numbers of animals in each study, see 
Husbandry in Methods and Procedures section.
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(http://www.ncbi.nlm.nih.gov/SNP/MouseSNP.cgi). A number 
of studies have explored the hypothesis that the common, non-
conservative variant, LEPR Q223R, predisposes to increased adi-
posity in humans. Interest in LEPR in this regard derives from its 
central role in energy homeostasis and the high frequency of this 
allele in most populations. The results, as noted, have been mixed, 
and two meta-analyses (17,47) have concluded that LEPR Q223R 
is not associated with relative adiposity or obesity. We used the 
mouse to attempt to make a more definitive finding regarding the 
biological significance of these alleles of LEPR.
129P3/J mice were transgenically engineered to segregate 
for the human alleles of LEPR at codon 223. Weight and body 
composition were assessed in male and female mice fed LF 
and HF diets over 235 days. Mice were also studied by indi-
rect calorimetry. No effect of the Lepr Q223R genotype was 
observed for any of the metabolic or body weight/composition 
phenotypes. Possible reasons for our failure to detect any func-
tional consequence of amino acid substitution at this locus 
include: (i) use of Lepr DNA sequence from a mouse strain with 
unique characteristics rendering the molecule insensitive to 
the allelic variant; (ii) a corollary possibility related to interac-
tions between the mouse Lepr sequence and the “background” 
genome of the mice examined in this study; (iii) the presence 
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Figure 4 Metabolic studies of mice fed the high-fat (HF) or low-fat (LF) diet. Indirect calorimetry performed on mice homozygous for the 223Q or 
223R Lepr alleles fed the LF or HF diets. Means and s.d. of (a) total body mass, (b) energy intake calculated from food intake, (c) respiratory quotient 
(RQ), (d) time course of oxygen utilization per hour over body mass raised to the 2/3 power (dark background represents hours with lights out) and 
(e) energy expenditure. Measurements were taken every ~14 min over a period of 72 h. Columns and error bars represent means of respective 
readings and s.d., respectively. For numbers in each study, see Calorimetry in Results section.
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Figure 5 In vitro assessment of leptin receptor activity. Activation of 
STAT3 in response to leptin stimulation. HEK 293 cells were transfected 
with the LeprΔ65C (truncated Lepr), LeprbQ223 (native mouse Lepr) 
and LeprbR223 (“humanized” Lepr) plasmids, as well as the STAT3-
responsive GAS-luciferase and control pRL-TK plasmids. Following 
transfection, cells were made quiescent, then treated with leptin for 
6 h before lysis. Leptin doses were 0, 20 ng/ml, 200 ng/ml, and 2 mg/
ml. Lysates were either subjected to (a) dual luciferase analysis or 
(b) resolved by SDS–PAGE before transferring to nitrocellulose and 
immunoblot with the indicated antibody. Bars represent the means of 
triplicate determinations plus or minus the s.d.
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of critical differences between mouse and human amino acid 
sequences in LEPR limiting the impact of the Q223R on a rel-
evant signaling pathway. With regard to (i), there are no cod-
ing or intronic splice site sequence differences in Lepr among 
mouse strains examined to date (NCBI; http://www.ncbi.nlm.
nih.gov/SNP/MouseSNP.cgi; database includes sequence from 
125 mouse strains). Point (ii) is addressed in the penultimate 
paragraph of the article, just below. With regard to (iii), the 
mouse LEPRb is ~75% identical at the amino acid level to the 
human protein (mLEPRb NCBI accession no. CAA71342; 
Human LEPRb NCBI accession no. NP_002294). In particu-
lar, mLEPRb residues associated with Janus kinase 2 (human 
residues 893–898) (ref. 48), STAT3 (human residues 1,142–
1,145) (ref. 49), SOCS3 (human residue 1,142; 27), STAT5 
(human residues 1,079–1,082) (refs. 23,50), SHP-2 (human 
residues 987–990 including Tyr 987 involved in the genera-
tion of mLEPRb autoinhibitory signals) (27,51) activities are 
conserved between mouse and human proteins. Similarly, the 
extracellular domain responsible for leptin binding (mouse 
residues 323–640) is 85% identical between mouse and human 
LEPR (34). Specifically, residues within sites I–III modeled to 
bind leptin are conserved in both mouse and human (36,52).
The LEPR Q223R substitution is located in the loop con-
necting the cytokine receptor (CK) and the fibronectin type 
III (F3) domains of CRH1 (Figure 1a). Residues in the Ig-like 
(36), CRH2 (ref. 35), and membrane-proximal F3 (ref. 53) 
domains have been implicated in LEPR function. No role has 
yet been assigned to CRH1 because it is not necessary for lep-
tin binding or LEPR activity (36). CRH1 and CRH2 are 23% 
identical at the amino acid level. Despite the conservation of 
critical CRH2 residues in CRH1, the Q223R polymorphism 
lies in a region unique to CRH1 (Figure 6), that is not con-
served in a number of related cytokine receptors (34). In 
contrast, the mutation that underlies the leptin insensitivity 
of fatty rats (Q269P) lies within an important structural sub-
domain of CRH1, and the Q269P substitution presumably 
destabilizes the structure of CRH1 and thus the entire LEPR 
molecule (34,54,55). Whatever the functional role (if any) of 
the LEPR Q223R polymorphism may be, it does not appear 
to affect leptin signaling as reflected by in vitro activation of 
STAT3, or the body composition/metabolic performance of 
mice studied over relatively long periods of time. We conclude 
from the present analysis that LEPR Q223R is unlikely to play 
a significant role in risk of human obesity.
The previous association detected in the human associa-
tion studies may be due to another polymorphism in linkage 
disequilibrium with LEPR Q223R, or could simply be a spuri-
ous finding. There is an important caveat to our conclusions 
regarding the likely absence of functional consequences of the 
Q223R alleles of LEPR. We examined the effects of these alle-
les in a single mouse strain (129P3/J). It is well known that 
the phenotypic “penetrance” of spontaneous and engineered 
mutations varies widely depending upon the strain(s) in which 
the mutation is segregated. The striking differences in diabetes-
related phenotypes of Leprdb mutations on the C57BLKS/J and 
C57BL/6J backgrounds (56) is a relevant example. This sort of 
effect may also account for apparent racial differences in the 
phenotypic consequences of genetic variation in humans (e.g., 
TCF7L2) (ref. 57). Clearly, studies of the sort described here 
must be interpreted in the context of such considerations. In 
this instance, given the discordant results in human studies, 
our in vivo results in 129 mice, and our in vitro analysis of sign-
aling by the Q223R alleles, we conclude that Q223R allelic var-
iation in LEPR plays a small role (if any) in human adiposity.
The approach used here was designed to provide a prototype 
for biological assessment of potentially small effects of allelic 
variants in candidate genes for complex convergent phenotypes 
such as human obesity. This approach can be used to examine 
alleles of several genes at one time, to recapitulate implicated 
haplotypes without confounding due to other genetic varia-
tion, or variable environments.
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